跳至主要内容
临床试验/NCT04326959
NCT04326959Unknown1 期

Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study

PT. Prodia Stem Cell Indonesia0 个研究点目标入组 24 人开始时间: 2020年9月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
入组人数
24
主要终点
Alfa SMA-1

研究概览

简要总结

The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020. Clinical trials of Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) and Conditioned Medium Umbilical Cord-Mesenchymal Stem Cells (CM UC-MSCs) for Keloid were designed in three groups. Group 1 injected with The UC-MSCs at a dose of 2 million cells / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at a dose of 1 cc / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at the same dose 3 weeks later. Group 3 injected with Triamcinolon acetonide (TA) at a dose of 40 mg / cc / cm3 using 1 cc (27 G) syringe and booster with TA at 3 weeks later. The study subjects each group amounted to 7 patients suffering from Keloid. Patients were evaluated for 3 months after injection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Surgery history of more than 3 months
  • •Has keloid that the maximum size is 15 cm and thickness is 3-5 mm

排除标准

  • •Patients with kidney failure
  • •Pregnancy
  • •Breastfeeding
  • •Liver dysfunction
  • •Blood disorders
  • •Currently receiving immunosuppressant therapy (chemotherapy or steroids)
  • •Refusing to participate in the study

研究组 & 干预措施

UC-MSCs + CM

Experimental

A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.

干预措施: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium (Biological)

UC-MSCs + CM

Experimental

A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.

干预措施: Conditioned Medium (Biological)

CM + CM

Experimental

A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.

干预措施: Conditioned Medium (Biological)

Triamcinolon acetonide

Experimental

A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.

干预措施: Triamcinolone Acetonide (Biological)

结局指标

主要结局

Alfa SMA-1

时间窗: 3 month after injection

Biomarker

Collagen type 1

时间窗: 3 moth after injection

Biomarker

次要结局

  • Core Biopsy/Histopathology(3 month after injection)
  • Ultrasonography(3 month after injection)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验